Pfizer’s pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib has been approved in the US as a treatment for some forms of lung cancer.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.